新股消息 | 景泽生物递表港交所 共有八个候选药物 其中三个产品处于后期阶段

Core Viewpoint - Jingze Biopharmaceutical (Hefei) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guoyuan International as joint sponsors [1] Company Overview - Jingze Biopharmaceutical focuses on high-growth sectors of assisted reproductive drugs and ophthalmic drugs, establishing a comprehensive R&D system and commercial-scale production capabilities [4] - The company has developed multiple product pipelines and advanced several high-tech barrier drugs to late clinical and commercialization stages [4] - As of June 20, 2025, Jingze is one of the leading companies in China for clinical-stage macromolecular drugs in the fields of assisted reproduction and ophthalmology [4] Product Pipeline - The company has a rich product pipeline with eight candidate drugs, three of which are in late-stage development, including one that has received NDA approval and another that has submitted NDA [5] - JZB30, the first commercialized product in assisted reproduction, is a recombinant human follicle-stimulating hormone (rhFSH) lyophilized powder injection, targeting the global ovulation induction market [5][6] - JZB05, an anti-VEGF intravitreal injection, is expected to be the first commercialized product in the ophthalmic field, with ongoing Phase III clinical trials [6] Financial Overview - Research and development expenses for 2023 and 2024 are approximately RMB 122.2 million and RMB 133.3 million, respectively [6] - The total loss for the years 2023 and 2024 is approximately RMB 246.2 million and RMB 242.7 million, respectively [7] - Other income and gains for 2023 and 2024 are RMB 9.8 million and RMB 12.4 million, respectively [7]